<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4248">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728906</url>
  </required_header>
  <id_info>
    <org_study_id>120/KEPK-RSB/X/20</org_study_id>
    <nct_id>NCT04728906</nct_id>
  </id_info>
  <brief_title>Heart Patch for Myocardial Infarction COVID-19</brief_title>
  <official_title>Targeted-cell Therapy Using Epithelial Stem Cells and Patients' Cardiomyocytes Loaded in Amnion Bilayer to Regenerate Myocardial Infarction Post COVID-19 Complication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rumah Sakit Pusat Angkatan Darat Gatot Soebroto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rumah Sakit Pusat Angkatan Darat Gatot Soebroto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocardial infarction (MI), as one of the many complications of COVID-19, is one of the&#xD;
      contributing patients of patients' death. This study attempts on developing an intervention&#xD;
      of MI by regenerating damaged cardiomyocytes due to insufficiency of oxygen in cardiac&#xD;
      muscles, triggered by an occlusion of coronary artery (MI). Heart patch developed from amnion&#xD;
      bilayer seeded with amnion epithelial stem cells and patient's autologous cardiomyocytes is&#xD;
      used as a therapy. Patients who undergo bypass (CABG) surgery are given heart patch, and then&#xD;
      patients condition are observed by ECG, Echo, blood test, and radiology (technetium-99m)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 5, 2021</start_date>
  <completion_date type="Anticipated">December 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of the ischemic burden (%)</measure>
    <time_frame>Comparison from the imaging within 3 months before intervention, and after 6 months post treatment.</time_frame>
    <description>Diagnosed by Technetium-99m radiology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the regional heart wall motion abnormality</measure>
    <time_frame>Observation of the heart wall motion by 1 week before intervention and 4 - 12 - 24 weeks after intervention</time_frame>
    <description>measured using Echocardiographic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the electrocardiographic wave</measure>
    <time_frame>Observation of electrocardiogram records by 1 week before intervention and 4 - 12 - 24 weeks after intervention</time_frame>
    <description>Measured using electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the ejection fraction</measure>
    <time_frame>Observation of the heart motion by 1 week before intervention and 4 - 12 - 24 weeks after intervention</time_frame>
    <description>Measured using echocardiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Heart patch + cardiomyocytes - hAESC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergo bypass (CABG) surgery are given heart patch in areas where grafting (bypass) is not feasible</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells</intervention_name>
    <description>heart patch is seeded with patient's cardiomyocytes (taken from patient's heart waste tissue when undergoing bypass surgery) and stock amnion epithelial stem cells (HLA-DR negative to eliminate risk of rejection)</description>
    <arm_group_label>Heart patch + cardiomyocytes - hAESC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 40 - 60 years old&#xD;
&#xD;
          -  Scanning of Technetium-99 shows ischemic burden &gt;10% and ischemic gradients red-violet&#xD;
&#xD;
          -  Ischemic area is not feasible to be grafted (bypass) due to other conditions such as&#xD;
             diffusion and deep intramuscular vascularization&#xD;
&#xD;
          -  Ejection fraction &gt;30-35%&#xD;
&#xD;
          -  Euro score &lt;8&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Scanning of Technetium-99 showed black colored ischemic area&#xD;
&#xD;
          -  Patients undergoing other procedures other than bypass such as valve repair&#xD;
&#xD;
          -  Chronic kidney failure&#xD;
&#xD;
          -  Patients have went through several bypass surgeries prior&#xD;
&#xD;
          -  Patients are still COVID-19 positive&#xD;
&#xD;
          -  Immunocompromised patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Normalina Sandora, MD, PhD</last_name>
    <phone>+62 812-9896-3425</phone>
    <email>normalinasandora@gmail.com</email>
  </overall_contact>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

